Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus

Shuliu Zhang, Matthew R. Vogt, Theodore Oliphant, Michael Engle, Evgeniy I. Bovshik, Michael S. Diamond, David Beasley

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Previous studies have established the therapeutic efficacy of humanized E16 (hE16) monoclonal antibody against West Nile virus in animals. Here, we assess the potential for West Nile virus strains encoding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutralization escape variants during hE16 treatment. Resistance to hE16 in vivo was less common than expected, because several mutations that affected neutralization in vitro did not significantly affect protection in mice. Moreover, the emergence of resistant variants after infection with fully sensitive virus occurred but was relatively rare, even in highly immunocompromised B and T cell-deficient RAG mice.

Original languageEnglish (US)
Pages (from-to)202-205
Number of pages4
JournalJournal of Infectious Diseases
Volume200
Issue number2
DOIs
StatePublished - Jul 15 2009

Fingerprint

West Nile virus
Neutralizing Antibodies
Antibodies, Monoclonal, Humanized
Mutation
Passive Immunization
Epitopes
B-Lymphocytes
Viruses
T-Lymphocytes
Therapeutics
Infection
In Vitro Techniques

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. / Zhang, Shuliu; Vogt, Matthew R.; Oliphant, Theodore; Engle, Michael; Bovshik, Evgeniy I.; Diamond, Michael S.; Beasley, David.

In: Journal of Infectious Diseases, Vol. 200, No. 2, 15.07.2009, p. 202-205.

Research output: Contribution to journalArticle

Zhang, Shuliu ; Vogt, Matthew R. ; Oliphant, Theodore ; Engle, Michael ; Bovshik, Evgeniy I. ; Diamond, Michael S. ; Beasley, David. / Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus. In: Journal of Infectious Diseases. 2009 ; Vol. 200, No. 2. pp. 202-205.
@article{934868427601458ba804cb1b089cbd68,
title = "Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus",
abstract = "Previous studies have established the therapeutic efficacy of humanized E16 (hE16) monoclonal antibody against West Nile virus in animals. Here, we assess the potential for West Nile virus strains encoding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutralization escape variants during hE16 treatment. Resistance to hE16 in vivo was less common than expected, because several mutations that affected neutralization in vitro did not significantly affect protection in mice. Moreover, the emergence of resistant variants after infection with fully sensitive virus occurred but was relatively rare, even in highly immunocompromised B and T cell-deficient RAG mice.",
author = "Shuliu Zhang and Vogt, {Matthew R.} and Theodore Oliphant and Michael Engle and Bovshik, {Evgeniy I.} and Diamond, {Michael S.} and David Beasley",
year = "2009",
month = "7",
day = "15",
doi = "10.1086/599794",
language = "English (US)",
volume = "200",
pages = "202--205",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Development of resistance to passive therapy with a potently neutralizing humanized monoclonal antibody against West Nile virus

AU - Zhang, Shuliu

AU - Vogt, Matthew R.

AU - Oliphant, Theodore

AU - Engle, Michael

AU - Bovshik, Evgeniy I.

AU - Diamond, Michael S.

AU - Beasley, David

PY - 2009/7/15

Y1 - 2009/7/15

N2 - Previous studies have established the therapeutic efficacy of humanized E16 (hE16) monoclonal antibody against West Nile virus in animals. Here, we assess the potential for West Nile virus strains encoding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutralization escape variants during hE16 treatment. Resistance to hE16 in vivo was less common than expected, because several mutations that affected neutralization in vitro did not significantly affect protection in mice. Moreover, the emergence of resistant variants after infection with fully sensitive virus occurred but was relatively rare, even in highly immunocompromised B and T cell-deficient RAG mice.

AB - Previous studies have established the therapeutic efficacy of humanized E16 (hE16) monoclonal antibody against West Nile virus in animals. Here, we assess the potential for West Nile virus strains encoding mutations in the hE16 epitope to resist passive immunotherapy and for the selection of neutralization escape variants during hE16 treatment. Resistance to hE16 in vivo was less common than expected, because several mutations that affected neutralization in vitro did not significantly affect protection in mice. Moreover, the emergence of resistant variants after infection with fully sensitive virus occurred but was relatively rare, even in highly immunocompromised B and T cell-deficient RAG mice.

UR - http://www.scopus.com/inward/record.url?scp=67650697066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650697066&partnerID=8YFLogxK

U2 - 10.1086/599794

DO - 10.1086/599794

M3 - Article

C2 - 19527169

AN - SCOPUS:67650697066

VL - 200

SP - 202

EP - 205

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -